A Neuroradiologist’s Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults

REFERENCES

1. 1.↵
   1. Ostrom QT,
   2. Price M,
   3. Neff C, et al

   . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016–2020. Neuro Oncol 2023;25:iv1–99 doi:10.1093/neuonc/noad149 pmid:37793125

   CrossRefPubMed
2. 2.↵
   1. Weller M,
   2. van den Bent M,
   3. Preusser M, et al

   . EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18:170–86 doi:10.1038/s41571-020-00447-z pmid:33293629

   CrossRefPubMed
3. 3.↵
   1. Wen PY,
   2. Weller M,
   3. Lee EQ, et al

   . Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 2020;22:1073–113 doi:10.1093/neuonc/noaa106 pmid:32328653

   CrossRefPubMed
4. 4.↵
   1. Ellingson BM,
   2. Wen PY,
   3. van den Bent MJ, et al

   . Pros and cons of current brain tumor imaging. Neuro Oncol 2014;16 Suppl 7:vii2–11 doi:10.1093/neuonc/nou224 pmid:25313235

   CrossRefPubMed
5. 5.↵
   1. Wen PY,
   2. Cloughesy TF,
   3. Ellingson BM, et al

   . Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol 2014;16 Suppl 7:vii36–47 doi:10.1093/neuonc/nou226 pmid:25313237

   CrossRefPubMed
6. 6.↵
   1. Lamborn KR,
   2. Yung WKA,
   3. Chang SM, et al

   . Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008;10:162–70 doi:10.1215/15228517-2007-062 pmid:18356283

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Wen PY,
   2. Macdonald DR,
   3. Reardon DA, et al

   . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol Off J Am Soc Clin Oncol 2010;28:1963–72 doi:10.1200/JCO.2009.26.3541 pmid:20231676

   CrossRefPubMed
8. 8.↵
   1. van den Bent MJ,
   2. Wefel JS,
   3. Schiff D, et al

   . Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011;12:583–93 doi:10.1016/S1470-2045(11)70057-2 pmid:21474379

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Ellingson BM,
   2. Wen PY,
   3. Cloughesy TF

   . Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurother J Am Soc Exp Neurother 2017;14:307–20 doi:10.1007/s13311-016-0507-6 pmid:28108885

   CrossRefPubMed
10. 10.↵
    1. Wen PY,
    2. Van Den Bent MJ,
    3. Youssef G, et al

    . RANO 2.0: Update to the Response Assessment in Neuro-Oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol 2023;41:5187–99 doi:10.1200/JCO.23.01059 pmid:37774317

    CrossRefPubMed
11. 11.↵
    1. Louis DN,
    2. Perry A,
    3. Wesseling P, et al

    . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076

    CrossRefPubMed
12. 12.↵
    1. Youssef G,
    2. Rahman R,
    3. Bay C, et al

    . Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 2023;41:3160–71 doi:10.1200/JCO.22.01579 pmid:37027809

    CrossRefPubMed
13. 13.↵
    1. Ellingson BM,
    2. Sampson J,
    3. Achrol AS, et al

    . Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. Clin cancer Res an Off J Am Assoc Cancer Res 2021;27:3916–25 doi:10.1158/1078-0432.CCR-21-0446 pmid:33863808

    CrossRefPubMed
14. 14.↵
    1. Ellingson BM,
    2. Bendszus M,
    3. Boxerman J, et al

    . Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol 2015;17:1188–98 doi:10.1093/neuonc/nov095 pmid:26250565

    CrossRefPubMed
15. 15.↵
    1. Sanvito F,
    2. Kaufmann TJ,
    3. Cloughesy TF, et al

    . Standardized brain tumor imaging protocols for clinical trials: current recommendations and tips for integration. Front Radiol 2023;3. doi:10.3389/fradi.2023.1267615 pmid:38152383

    CrossRefPubMed
16. 16.↵
    1. Ellingson BM,
    2. Kim GHJ,
    3. Brown M, et al

    . Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib. Neuro Oncol 2022;24:770–8 doi:10.1093/neuonc/noab256 pmid:34751786

    CrossRefPubMed
17. 17.↵
    1. Boxerman JL,
    2. Quarles CC,
    3. Hu LS, et al

    . Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. Neuro Oncol 2020;22:1262–75 doi:10.1093/neuonc/noaa141 pmid:32516388

    CrossRefPubMed
18. 18.↵
    1. Ellingson BM,
    2. Brown MS,
    3. Boxerman JL, et al

    . Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials. Neuro Oncol 2021;23:189–98 doi:10.1093/neuonc/noaa253 pmid:33130879

    CrossRefPubMed
19. 19.↵
    1. Ellingson BM,
    2. Abrey LE,
    3. Garcia J, et al

    . Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. Neuro Oncol 2018;20:1525–35 doi:10.1093/neuonc/noy064 pmid:29897562

    CrossRefPubMed
20. 20.↵
    1. Ellingson BM,
    2. Gerstner ER,
    3. Lassman AB, et al

    . Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. Neuro Oncol 2022;24:1219–29 doi:10.1093/neuonc/noac086 pmid:35380705

    CrossRefPubMed
21. 21.↵
    1. Huang RY,
    2. Rahman R,
    3. Ballman K V, et al

    . The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin cancer Res an Off J Am Assoc Cancer Res 2016;22:575–81 doi:10.1158/1078-0432.CCR-14-3040 pmid:26490307

    CrossRefPubMed
22. 22.↵
    1. Seymour L,
    2. Bogaerts J,
    3. Perrone A, et al

    . iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18:e143–52 doi:10.1016/S1470-2045(17)30074-8 pmid:28271869

    CrossRefPubMed
23. 23.↵
    1. Carr CM,
    2. Benson JC,
    3. DeLone DR, et al

    . Intracranial long-term complications of radiation therapy: an image-based review. Neuroradiology 2021;63:471–82 doi:10.1007/s00234-020-02621-7 pmid:33392738

    CrossRefPubMed
24. 24.↵
    1. Kickingereder P,
    2. Isensee F,
    3. Tursunova I, et al

    . Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. Lancet Oncol 2019;20:728–40 doi:10.1016/S1470-2045(19)30098-1 pmid:30952559

    CrossRefPubMed
25. 25.↵
    1. Watling CJ,
    2. Lee DH,
    3. Macdonald DR, et al

    . Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol Off J Am Soc Clin Oncol 1994;12:1886–9 doi:10.1200/JCO.1994.12.9.1886 pmid:8083712

    CrossRefPubMed
26. 26.↵
    1. Dietrich J,
    2. Rao K,
    3. Pastorino S, et al

    . Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol 2011;4:233–42 doi:10.1586/ecp.11.1 pmid:21666852

    CrossRefPubMed